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Melioidosis is a potentially fatal disease caused by the saprophytic bacterium Burkholderia pseudomallei. Resistance to gen-
tamicin is generally a hallmark of B. pseudomallei, and gentamicin is a selective agent in media used for diagnosis of melioidosis.
In this study, we determined the prevalence and mechanism of gentamicin susceptibility found in B. pseudomallei isolates from
Sarawak, Malaysian Borneo. We performed multilocus sequence typing and antibiotic susceptibility testing on 44 B. pseudomal-
lei clinical isolates frommelioidosis patients in Sarawak district hospitals. Whole-genome sequencing was used to identify the
mechanism of gentamicin susceptibility. A novel allelic-specific PCR was designed to differentiate gentamicin-sensitive isolates
from wild-type B. pseudomallei. A reversion assay was performed to confirm the involvement of this mechanism in gentamicin
susceptibility. A substantial proportion (86%) of B. pseudomallei clinical isolates in Sarawak, Malaysian Borneo, were found to
be susceptible to the aminoglycoside gentamicin, a rare occurrence in other regions where B. pseudomallei is endemic. Gentami-
cin sensitivity was restricted to genetically related strains belonging to sequence type 881 or its single-locus variant, sequence
type 997. Whole-genome sequencing identified a novel nonsynonymous mutation within amrB, encoding an essential compo-
nent of the AmrAB-OprAmultidrug efflux pump.We confirmed the role of this mutation in conferring aminoglycoside and
macrolide sensitivity by reversion of this mutation to the wild-type sequence. Our study demonstrates that alternative B. pseu-
domallei selective media without gentamicin are needed for accurate melioidosis laboratory diagnosis in Sarawak. This finding
may also have implications for environmental sampling of other locations to test for B. pseudomallei endemicity.
Melioidosis is a potentially fatal disease endemic in South-east Asia, northern Australia, and other tropical regions.
Melioidosis is caused by the saprophytic bacterium Burkholderia
pseudomallei, commonly found in the environment in regions of
endemicity, with infection generally occurring from contact with
contaminated water or soils (1). Clinical presentations of melioid-
osis are highly variable and can manifest as asymptomatic infec-
tions, localized skin abscess formation, acute or chronic pneumo-
nia, genitourinary, bone, and joint infections, or severe systemic
sepsis, with or without foci of multiple abscesses in internal or-
gans, with a mortality of90% in septic shock cases (2, 3). Due in
part to the high virulence of this organism and increased concerns
for transmission by aerosolization, B. pseudomallei was upgraded
to a tier 1 select agent by the U.S. Centers for Disease Control and
Prevention in 2012 (http://www.selectagents.gov/).
B. pseudomallei is intrinsically resistant to a wide range of an-
tibiotics, including many -lactams, aminoglycosides, and mac-
rolides (4–6). This array of drug resistance is conferred through a
variety of mechanisms, including inactivating enzymes, cell exclu-
sion, and broad-range efflux pumps. Although almost all B. pseu-
domallei strains are resistant to the aforementioned antibiotics,
there have been reports of rare (0.1%) aminoglycoside and mac-
rolide susceptibility in isolates from Thailand (7, 8) and in a
chronic-carriage patient from Australia (9). Aminoglycoside and
macrolide resistance in B. pseudomallei is thought to be conferred
solely by the multidrug efflux pump AmrAB-OprA (10, 11).
In the present study, we identified aminoglycoside and mac-
rolide sensitivity in B. pseudomallei isolates of clinical origin from
a wide geographical region within Sarawak, Malaysian Borneo.
Antibiotic susceptibility was confined to closely related isolates
based on multilocus sequence typing (MLST). Using whole-ge-
nome sequencing (WGS), we identified a nonsynonymous muta-
tion within the multidrug efflux pump, AmrAB-OprA. Reversion
of this mutation restored aminoglycoside and macrolide resis-
tance.
MATERIALS AND METHODS
Ethics.Bacterial strain collection and research were approved by the Med-
ical Research Ethics Committee and registered with the National Medical
Research Registrar and the Clinical Research Centre, Ministry of Health of
Malaysia. All clinical isolates were from routine melioidosis laboratory
diagnosis, and hence no written consent was obtained from patients.
Bacterial strains. The B. pseudomallei strains used in this study are
listed in Table 1. With the exception of MSHR7596, MSHR7597,
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MSHR7598, and MSHR7599, which were derived from MSHR6808, all
other strains were collected from melioidosis cases from four hospitals,
located in Bintulu, Kapit, Miri, and Sibu, Malaysia. Strains were grown at
37°C for 24 h on tryptic soy agar (TSA) (Oxoid, Australia), regular Ash-
down’s agar (Oxoid), or Ashdown’s agar without gentamicin (GEN) con-
taining an additional 50 g/ml colistin.
MLST. MLST was performed using previously published methods
(12).
Antibiotic sensitivity testing. MICs were determined using Etests
(bioMérieux, France) according to the manufacturer’s instructions. B.
pseudomallei strains were grown for 24 h before MIC determination. GEN
MIC values for susceptible, intermediate, and resistant were defined as4
g/ml, 8 g/ml, and16 g/ml, respectively (5, 6).
WGS and analysis. WGS was performed on six B. pseudomallei iso-
lates (MSHR5087, MSHR5089, MSHR5102, MSHR5104, MSHR5105,
and MSHR5107), using an Illumina GAIIx platform according to stan-
dard protocols. WGS data were aligned to the B. pseudomallei K96243
sequence (13) by using Burrows-Wheeler Aligner (14), with subsequent
conversion to binary alignment map (bam) format by using SAMtools
(15). Single nucleotide polymorphisms (SNPs) and indels were called by
TABLE 1 B. pseudomallei isolates used in this study
Strain Source
Location or
reference STb
GEN
phenotype
MSHR5079 No clinical information Kapit 50 GENr
MSHR5084 67-yr-old female with osteomyelitis; blood culture Bintulu 658 GENr
MSHR5087a 3-yr-old female; abscess on scalp Kapit 881 GENs
MSHR5089a 45-yr-old female Kapit 881 GENs
MSHR5091 3-yr-old female; abscess Kapit 881 GENs
MSHR5093 62-yr-old female with community-acquired pneumonia; blood culture Kapit 881 GENs
MSHR5095 41-yr-old male with pneumonia; blood culture Bintulu 881 GENs
MSHR5097 34-yr-old male; blood culture Bintulu 881 GENs
MSHR5102a 17-yr-old male; neutropenic sepsis Bintulu 658 GENr
MSHR5104a 53-yr-old female; blood culture Bintulu 881 GENs
MSHR5105a 2-yr-old female; pus from left cervical lymphadenitis Bintulu 881 GENs
MSHR5107a 18-yr-old male; pus from neck abscess Kapit 881 GENs
MSHR6381 47-yr-old male; shoulder abscess Kapit 881 GENs
MSHR6385 2-yr-old female with severe community-acquired pneumonia; blood culture Kapit 881 GENs
MSHR6386 27-yr-old male with community-acquired pneumonia; blood culture Kapit 881 GENs
MSHR6387 89-yr-old male with community-acquired pneumonia; blood culture Kapit 881 GENs
MSHR6389 11-yr-old male; lower right eyelid and right cervical abscess, pus Sibu 881 GENs
MSHR6390 30-yr-old male with community-acquired pneumonia Sibu 881 GENs
MSHR6392 18-yr-old male; ankle abscess Sibu 881 GENs
MSHR6401 61-yr-old male with community-acquired pneumonia; blood culture Sibu 881 GENs
MSHR6404 12-yr-old female; pus from lower eyelid abscess Sibu 881 GENs
MSHR6408 No clinical information Sibu 881 GENs
MSHR6409 51-yr-old male with community-acquired pneumonia; blood culture Sibu 881 GENs
MSHR6410 45-yr-old male with knee septic abscess; blood culture Sibu 881 GENs
MSHR6411 27-yr-old male with community-acquired pneumonia; blood culture Sibu 881 GENs
MSHR6414 41-yr-old male with ankle septic arthritis Sibu 881 GENs
MSHR6415 54-yr-old female with sepsis secondary to right leg wound Kapit 881 GENs
MSHR6418 15-mo-old female with occipital abscess; culture positive from abscess Bintulu 881 GENs
MSHR6419 48-yr-old male with community-acquired pneumonia Bintulu 50 GENr
MSHR6769 41-yr-old male with severe pneumonia with sepsis; blood culture Bintulu 881 GENs
MSHR6774 14-yr-old male; pus from cervical abscess Kapit 881 GENs
MSHR6778 11-yr-old female; neck abscess Kapit 881 GENs
MSHR6780 31-yr-old male; pus Kapit 881 GENs
MSHR6785 59-yr-old female; knee abscess Kapit 881 GENs
MSHR6789 12-yr-old male; blood culture Kapit 881 GENs
MSHR6793 37-yr-old female; blood culture Kapit 997 GENs
MSHR6802 3-yr-old female; septic shock blood culture. Sibu 881 GENs
MSHR6803 48-yr-old male Sibu 881 GENs
MSHR6806 37-yr-old female; blood culture Sibu 881 GENs
MSHR6816 34-yr-old male; blood culture Sibu 46 GENr
MSHR6822 41-yr-old male with ankle septic arthritis Sibu 881 GENs
MSHR6824 50-yr-old female with abscess and sepsis; blood culture Miri 271 GENr
MSHR6828 Female; blood culture Bintulu 881 GENs
MSHR6808 61-yr-old male with community-acquired pneumonia; blood culture Sibu 881 GENs
MSHR7596 Spontaneous GENr mutant derived from MSHR6808 This study ND GENr
MSHR7597 Spontaneous GENr mutant derived from MSHR6808 This study ND GENr
MSHR7598 Spontaneous GENr mutant derived from MSHR6808 This study ND GENr
MSHR7599 Spontaneous GENr mutant derived from MSHR6808 This study ND GENr
a Whole-genome sequencing was performed on this isolate.
b Sequence type as determined by multilocus sequence typing. ND, not determined.
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using GATK (16) with previously published parameters (9). Mutations
were assessed for change of function by using PROTEAN (17).
AS-PCR. A novel allele-specific PCR (AS-PCR) assay was designed to
differentiate amrB mutants from wild-type B. pseudomallei isolates. Al-
lele-specific PCR was performed as previously described (18), using one
allele-specific forward primer (Invitrogen, Australia) (GmS_F_mut [5=-T
CCGCGCGACGCTGATTCCGtG-3=] or GmS_F_wt [5=-TCCGCGCGA
CGCTGATTCCGtC-3=]) and a common reverse primer (GmS_R_com
[5=-ACGTGAGCACGACGGTGATCC-3=]) in each reaction mixture.
Underlined nucleotides represent SNP targets that match the wild-type or
mutant allele, respectively. Lowercase nucleotides represent a deliberately
incorporated penultimate mismatch to enhance allele specificity (19).
Restoration of aminoglycoside resistance. Aminoglycoside-sensitive
B. pseudomallei isolates were grown in 50 ml tryptic soy broth (Oxoid) at
37°C with shaking at 180 rpm for 18 to 24 h. The bacterial culture was
centrifuged at 4,000 rpm for 10 min to pellet cells. The majority of the
supernatant was removed and the bacterial cells spread on TSA (Oxoid)
containing 40 g/ml gentamicin (Pfizer) and 30 g/ml kanamycin
(Sigma, Germany). Plates were incubated for 48 h at 37°C. Mutant colo-
nies were purified and retained for further analysis.
Dideoxy sequencing. Dideoxy sequencing of amrB was performed by
Macrogen (Seoul, South Korea). The following primers were designed
and used for amplification and sequencing of this locus: AmrBseq_F (5=-
GCCGGGCGTCAAGTACCAGATT-3=) and AmrBseq_R (5=-CTGATCT
GCTTCATCGCCTTCAC-3=).
Primer design. All primers were designed using Primer3 software
(20, 21).
Nucleotide sequence accession number. The nucleotide sequences
for amrB have been deposited in the GenBank database under accession
numbers KF548562 to KF548567.
RESULTS AND DISCUSSION
MLST of Sarawak isolates indicates a restricted geographical
distribution. MLST was performed on all B. pseudomallei isolates
collected in our study (Table 1), and sequence type (ST) profiles
were submitted to the B. pseudomallei MLST database (http:
//bpseudomallei.mlst.net/). Thirty-seven (84%) isolates were
ST881, with this ST forming the majority of samples from hospi-
tals in the central region of Sarawak (i.e., Bintulu, Kapit, and
Sibu). ST881 has been reported once previously, in a Chinese trav-
eler returning from working in the Malaysian jungle (22). The sole
isolate from the Miri hospital in northern Sarawak was ST271. The
remaining six isolates belonged to ST46, ST50, ST658, and ST997
(Table 1). With the exception of ST997, which is a single-locus
variant (SLV) of ST881, all other STs have been identified previ-
ously. ST658 has been found in Laos and Thailand. ST50 has been
found in China and Thailand and is an SLV of ST46 and a double-
locus variant of ST271. ST46 appears to be widespread and has
been reported in historical samples collected from peninsular Ma-
laysia in the 1960s (23) and from Bangladesh, Cambodia, India,
Thailand, Vietnam, and the United States, most probably from a
traveler to a region of endemicity. In contrast, ST271 appears
rarely and, to date, has been found only in Malaysian Borneo.
Sarawak is located in Malaysian Borneo, with rugged topogra-
phies resulting in areas with limited access and the existence of
subsistent indigenous communities. This ruggedness is especially
true in the central region, where ST881 and ST997 were isolated.
The apparent geographic restriction associated with limited se-
quence diversity of ST881 is similar to previous reports of B. pseu-
domallei isolates from Papua New Guinea, where low diversity of
B. pseudomalleiwas observed in a geographically isolated region of
Western Province (24, 25). The narrow genetic variability within
the majority of the Sarawak isolates and those from Papua New
Guinea could potentially reflect recent but independent introduc-
tion events in those two locations. More likely, however, the ob-
served overlap of certain STs in Malaysian Borneo with other
Asian regions supports the hypothesis of a more ancient dispersal
of B. pseudomallei to Malaysian Borneo, with dispersal and diver-
sity in Sarawak restricted by its remoteness, and potentially also by
limited anthropogenic activities (25).
ST881 and ST997 isolates are susceptible to aminoglycosides
and macrolides. All ST881 and ST997 isolates (n  38) were
shown to be susceptible to the aminoglycoside GEN, with MICs
ranging from 0.5 to 1.5g/ml (see Table S1 in the supplemental
material). In contrast, GEN MICs for wild-type B. pseudomallei
are approximately 128g/ml (7). GEN is a selective component of
Ashdown’s agar media used for B. pseudomallei detection and iso-
lation in regions of endemicity (26). In addition, the ST881 and
ST997 isolates were sensitive to kanamycin (also an aminoglyco-
side) and azithromycin (a macrolide), with MICs of 1.0 and 2.0
g/ml, respectively (see Table S1). All ST881 and ST997 isolates
were susceptible to the antibiotics used in treating melioidosis,
notably ceftazidime, meropenem, doxycycline, amoxicillin-clavu-
lanic acid, and trimethoprim-sulfamethoxazole, demonstrating
MICs similar to those for other wild-type B. pseudomallei strains.
Non-ST881/ST997 isolates collected in this study had MIC values
similar to those for other wild-type B. pseudomallei strains, with
sensitivity to the clinically relevant antibiotics and resistance to
GEN, kanamycin, and azithromycin (see Table S1).
WGS of four GEN-sensitive (GENs) isolates revealed a novel
cytosine (C)-to-guanine (G) transition located within amrB
(amrB-C1102G), which encodes the membrane-spanning com-
ponent of the resistance-nodulation-division family (RND) efflux
pump, AmrAB-OprA. This nonsynonymous SNP confers a thre-
onine-to-arginine substitution (T367R) in a highly conserved re-
gion of the protein. This substitution was predicted to be delete-
rious by PROTEAN (17). This mutation has not previously been
reported for any other sequenced B. pseudomallei isolate to date
(NCBI database as of 15 May 2013) (see Fig. S1 in the supplemen-
tal material). To rapidly interrogate the amrB-C1102G SNP in the
larger collection of isolates obtained in this study, we designed a
novel allelic-specific PCR (AS-PCR) assay. AS-PCR was able to
rapidly and accurately determine the SNP state at amrB position
1102 and confirmed that the mutation was restricted to B. pseu-
domallei isolates with the GENs phenotype. All strains in our study
that were GENr possessed the wild-type nucleotide at this posi-
tion.
Reversion of the C1102G mutation restores aminoglycoside
and macrolide resistance. To verify the role of amrB-C1102G in
aminoglycoside and macrolide sensitivity, we selected GENr mu-
tant derivatives of a GENs strain (MSHR6808) and interrogated
the amrB-C1102G SNP in the mutant strains. Of 95 GENr mu-
tants, AS-PCR identified 4 that were potentially mutated at amrB
position 1102. DNA sequence analysis confirmed that only
MSHR7599 reverted to the wild-type sequence at amrB (amrB-
G1102C) (R367T). Interestingly, MSHR7596, MSHR7597, and
MSHR7598 all possessed a novel thymine transversion at this po-
sition (amrB-G1102T), which altered the codon to a third config-
uration, resulting in a methionine substitution (R367M). The
GEN MICs for all four mutants were 256 g/ml, whereas the
original strain (MSHR6808) had an MIC of 0.75g/ml (see Table
S1 in the supplemental material). Similarly, the MIC for kanamy-
cin increased from 1.0 g/ml to 128 g/ml, and the MIC of azi-
Podin et al.
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thromycin increased from 1.5g/ml to between 32 and 128g/ml
(see Table S1). These MIC data indicate that methionine is an
effective substitute for threonine at this position and demonstrate
that B. pseudomallei has at least two different ways to develop
GENr at amrB position 1102. Interestingly, 91 of the 95 mutants
were unchanged at amrB position 1102; thus, multiple mecha-
nisms exist for acquiring GENr in B. pseudomallei. The genetic
bases for resistance in these mutants were not characterized in the
current study. Importantly, the restoration of the amrB-1102C
allele in one mutant, concomitant with acquisition of aminogly-
coside and macrolide resistance, is evidence that the C¡G substi-
tution in ST881 and ST997 confers aminoglycoside and macrolide
susceptibility.
Clinical and environmental significance of aminoglycoside-
andmacrolide-sensitive B. pseudomallei in Sarawak. The emer-
gence and persistence of ST881 and ST997 in Sarawak are not fully
understood. Our study has demonstrated that ST881 and ST997
can cause diseases in humans despite being susceptible to amin-
oglycosides and macrolides, suggesting that the loss of aminogly-
coside and macrolide resistance has little consequence for viru-
lence of these strains. However, it cannot be ruled out that this
mutation enhances environmental survival of ST881 and ST997.
Despite the aminoglycoside and macrolide sensitivity of the B.
pseudomallei strains in our study, patients infected with these
strains had similar clinical presentations and outcomes to those of
patients infected with the GENr B. pseudomallei strains in this
study (Table 1; see Table S1 in the supplemental material) and
other studies (1, 27–29). This observation is consistent with the
work of Trunck and coworkers, who reported unaltered virulence
in rare GENs isolates from clinical cases (8).
Furthermore, we have shown that the distribution of GENs
strains is not confined to a small geographic region; presumptive
locations of B. pseudomallei acquisition for the patients infected
with ST881 and ST997 strains span a large region within Malay-
sian Borneo, with an area of approximately 60,000 km2 encom-
passing the Bintulu, Kapit, and Sibu regions (see Fig. S2 in the
supplemental material). Although the GENs phenotype has previ-
ously been observed in B. pseudomallei, it has putatively been a
result of niche adaptation and genome decay and is very rare (8, 9).
To our knowledge, no other instances of clear phenotypic change
have been associated with a specific B. pseudomallei lineage, possi-
bly with the exception ofBurkholderiamallei, the causative agent of
glanders. B. mallei is a clone of B. pseudomallei which has under-
gone genome reduction and has become aminoglycoside sensitive
(30, 31). Unlike B. mallei, which has lost the entire AmrAB-OprA
efflux pump operon, our study identified a unique mechanism
leading to aminoglycoside and macrolide susceptibility in ST881
and ST997. Further genomic analysis of these strains would be
useful to determine whether they have undergone early stages of
genome decay similar to that seen in isolates from chronic-car-
riage patients (9). In addition, the existence or persistence of these
strains in the environment and whether susceptibility to amin-
oglycosides and macrolides affects their survival in the environ-
ment warrant further investigation.
Conclusion. In this study, we analyzed B. pseudomallei clinical
isolates from Sarawak, Malaysian Borneo, to determine both the
prevalence and molecular basis of GENs. The majority of these
isolates were of a single ST and were sensitive to aminoglycosides
and macrolides, a phenotype that is very rare in B. pseudomallei
strains from other regions of endemicity. Aminoglycoside sensi-
tivity was the result of a nonsynonymous SNP within amrB. Most
selective media for B. pseudomallei growth contain GEN as a se-
lective agent (26, 32, 33). Use of these media in Sarawak as a sole
diagnostic tool for melioidosis is problematic because, based on
our findings, approximately 86% of cases would not be diagnosed.
Alternative selective media without GEN (for example, Ash-
down’s medium supplemented with colistin instead of GEN) may
be a more appropriate option for laboratory diagnosis of sus-
pected melioidosis cases in Sarawak. Laboratory scientists and cli-
nicians in central Sarawak and surrounding regions should exer-
cise caution in confirming B. pseudomallei infection by use of
selective media containing GEN. Our findings have significant
implications for laboratory diagnosis and environmental sam-
pling of B. pseudomallei, particularly in Malaysian Borneo and
other potential regions of endemicity where B. pseudomallei has
yet to be uncovered.
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